Kalios
← Stacks

Stack — Injury & recovery

Wolverine Stack — BPC-157 + TB-500 · Tested together in people: none published

Gray market

Checked · 18 sources · 9 corrections on this page · No vendors · No affiliates · No one buys a word of it

BPC-157 and TB-500: FDA panel said yes on July 23–24, 2026 — not legal yet

Sold as a research chemical. Some clinics and pharmacies still supply it; that’s their risk, not a change in the rule.

Not legal to compound — yet The FDA’s advisory committee recommended BPC-157 and TB-500 on July 23–24, 2026. Recommended is not legal — nothing changes until rulemaking is finished. See every change →

Built on: Tissue Repair & Recovery

The receipt

0 studies gave them to people together

Evidence on the combination
Animal only

None published

No study that gave them to people together is among the sources Kalios cites. Reports of people already taking both, registered trials, conference talks, patents and makers’ own tests don’t count.

What each does alone

Mechanism overlap · reasoning, not evidence

BPC-157
Peptide — Tissue Repair & Cytoprotection
TB-500
Peptide Fragment — Tissue Repair (Thymosin β4 17–23)

Reasoning, not evidence: what each is described to do says nothing about what they do together.

References

No clinical trial has studied the BPC-157 + TB-500 combination in humans. The references below are for the individual components and mechanistic framework.

  1. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
  2. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983. PMID: 14554208.
  3. Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing. J Orthop Res. 2006;24(5):982-989. PMID: 16583442.
  4. Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID: 33051481.
  5. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID: 32334036.
  6. Vasireddi N, et al. The current state of BPC-157 in musculoskeletal medicine: a systematic review. J Orthop Surg Res. 2025;20(1). PMID: 40756949.
  7. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. PMID: 6940133.
  8. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145.
  9. Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474(7353):640-644. PMID: 21654746.
  10. Sosne G, Christopherson PL, Barrett RP, Fridman R. Thymosin-beta 4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci. 2005;46(7):2388-2395. PMID: 15980226.
  11. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294.
  12. Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci. 2007;1112:385-395. PMID: 17947592.
  13. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) — 503A / 503B list. FDA.gov, updated 2025.
  14. WADA. 2026 Prohibited List. Section S0 (BPC-157) and S2.3 (TB-500 / Tβ4). World Anti-Doping Agency.
  15. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
  16. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID: 42542926.
  17. FDA. July 23–24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate). Evaluation dated May 15, 2026. fda.gov/media/193349/download. Read October 3, 2026.
  18. Zhou B, Honor LB, Ma Q, Oh JH, et al. Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. J Mol Cell Cardiol. 2012;52(1):43-47. PMID: 21907210. DOI: 10.1016/j.yjmcc.2011.08.020.

→ Calculator — vial-to-syringe math

See every change to this page → · Status now →

Checked 13 Oct 2026